Indication
Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
Loading your page…
Loading your page…
Carcinoma, Basal Cell
Marketing Authorisation Holder: Roche Registration GmbH
EMA Authorisation: 12/07/2013
INN: vismodegib
AI Drug & Interaction Analysis
Free account required
Ask Osler about Erivedge: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.